11 results about "Radioresistance" patented technology

In the present invention, the mRNA of the genes VTN, CXCL5, NEDD4, LCN2, SYTL4, TNFR2, and SERPING1, or the proteins encoded by these genes, exhibit differential expression levels in radioresistant lung cancer cells compared to control lung cancer cells and have a close correlation with a decrease in the survival rate of lung cancer patients. Accordingly, this preparation for measuring the expression levels of the mRNA of the genes selected from the group consisting of VTN, CXCL5, NEDD4, LCN2, SYTL4, TNFR2, and SERPING1 of the present invention or the expression levels of the proteins encoded by the genes can effectively diagnose radiation resistance in lung cancer or prognose radiation therapy for lung cancer, whereby it is possible to determine whether to perform radiation therapy and the optimal dose of radiation therapy, thus improving the efficiency and therapeutic outcomes of radiation therapy for lung cancer.

The application discloses a kind of targeted nanomedicine for treating radiation-resistant NSCLC and its preparation method and application, and belongs to the medical technical field, wherein the preparation method of targeted nanomedicine includes the following steps: using NaGdF4 as core, mesoporous silica as carrier, NaGdF4 is coated, and radio-sensitizing nanomaterial is obtained;Radio-sensitizing nanomaterial is co-incubated with PD-1 protein, and the targeted nanomedicine for treating radiation-resistant NSCLC is obtained.The application regulates radiation-resistant NSCLC tumor immune microenvironment by constructing radiosensitizing nano platform and loading PD-1 protein, controls the proliferation, migration and invasion of radiation-resistant NSCLC cells, successfully reverses the radioresistance of NSCLC, and significantly enhances the response of resistant cells to radiotherapy.The method provides valuable insights for developing targeted nanotherapeutic drugs to effectively treat NSCLC.

The invention addresses radioresistance in cancer treatment involving radiotherapy and, in particular, limitations associated with the use of the drug sulfasalazine. Specifically, it provides a series of compounds for use as radiosensitizers in the treatment of cancers such as glioblastomas which are lethal and inherently resistant to radiotherapy. In one embodiment, the invention provides compounds of general formula (I), their stereoisomers and pharmaceutically acceptable salts for use as radiosensitizers in the treatment of cancer:wherein ring A is selected from optionally substituted phenyl, biphenyl and fluorenyl; each X is independently selected from: —C1-6 alkyl (preferably C1-3 alkyl, e.g. —CH3), —O—C1-6 alkyl (preferably —O—C1-3 alkyl, e.g. —OCH3), —S—C1-6 alkyl (preferably —S—C1-3 alkyl, e.g. —SCH3), —OH, —SH, —CO2R1 (where R1 is H or C1-6 alkyl, preferably C1-3 alkyl, e.g. —CH3), —SO2—C1-6 alkyl (preferably —SO2—C1-3 alkyl, e.g. —SO2—CH3), —SO2—NR2R3 (where R2 is H and R3 is optionally substituted phenyl), —NR4R5 (wherein R4 and R5 are independently selected from H, C1-6 alkyl (preferably C1-3 alkyl, e.g. —CH3), and —CO—C1-6 alkyl (preferably —CO—C1-3 alkyl, e.g. —CO—CH3), halogen (e.g. F, Cl or Br), and optionally substituted tetrazolyl; n is an integer from 0 to 5, preferably 0 to 2, e.g. 1 or 2; and denotes an E or Z double bond.

The application provides a kind of nanoparticle for radiotherapy-copper death combined treatment breast cancer and its preparation method and application, it is suitable for the preparation field of nanoparticle, wherein the nanoparticle includes the following raw materials: 10mg precipitate A, 3~8mg CuCl2, 10mg DA.HCl, 2~6mg BSO, 100~250ul Tris-HCl buffer solution and 30~40mg BSA;The precipitate A includes the following raw materials: the mass ratio of hafnium tetrachloride and polyvinylpyrrolidone is 8:5;With can be through exogenous delivery copper ion, make intracellular copper ion accumulation, induce copper death effect, combined radiotherapy and BSO, produce strong copper death, enhance the beneficial effect of tumor cell radiation absorption and antitumor immune effect, can effectively reverse radioresistance and tumor immunosuppression microenvironment.

The invention discloses a human esophageal cancer radiotherapy resistance cell strain and a construction method and application thereof, the human esophageal cancer radiotherapy resistance cell strain is named as human esophageal cancer radiotherapy resistance cell strain KYSE-150-RR homo sapiens, and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: C2025261, and the preservation date is September 24, 2025. The cell strain disclosed by the invention has important application prospects in the aspects of researching an esophageal cancer radiotherapy resistance mechanism, reversing radiotherapy resistance, developing a combined treatment medicine and establishing an animal model.

This invention relates to the application of DTX3 or reagents that promote DTX3 expression in the preparation of products reversing radioresistance in nasopharyngeal carcinoma (NPC), belonging to the field of biomedical technology. The invention found that, compared to parental NPC cells, Deltex E3 ubiquitin ligase 3 (DTX3) expression is significantly reduced in radioresistant NPC. Overexpression of DTX3 can reverse radioresistance in NPC cells and inhibit homologous recombination repair after radiotherapy in NPC, thus allowing DTX3 to be used to reverse radioresistance in NPC. This invention provides a new biomarker for the diagnosis of radiotherapy response in NPC, an effective method for reversing radioresistance in NPC, and a new treatment option for NPC.

The invention belongs to the field of biomedicine, and particularly relates to application of Ptpn6 knockout macrophages in breast cancer radiotherapy sensitization. Through experimental verification for the first time, Ptpn6 is determined as a key new target for regulating and controlling radiation response and functional phenotype of macrophages. The Ptpn6 gene of the macrophage is knocked out through a gene editing technology, the radiation resistance of the macrophage can be enhanced, the macrophage can continuously survive in a microenvironment after radiotherapy, the macrophage can be reprogrammed into an anti-tumor M1 sample phenotype from a tumor promoting M2 phenotype, and then the anti-tumor immunocompetence of the macrophage is enhanced. In-vitro and in-vivo experiments prove that compared with wild type macrophages, the Ptpn6 knockout macrophages can be used as a cell sensitizer to be combined with radiotherapy, so that the proliferation of tumor cells can be more effectively inhibited, the apoptosis of the tumor cells can be promoted, and the growth of in-vivo tumors can be obviously inhibited. A brand new cell treatment strategy is provided for overcoming breast cancer radiotherapy resistance.

The invention relates to the technical field of medicine preparation, in particular to application of cytokinin oTR in preparation of a medicine for enhancing tumor cell radiosensitivity. By constructing a stable tumor radiation resistance cell model and combining molecular biology experiments and statistical analysis, it is proved that cytokinin oTR can regulate and control expression of SIRT1 and miR-34a in radiation resistance cells in a time-dose dependence mode, and the radiotherapy sensitization effect is achieved through a p53 / miR-34a / SIRT1 pathway.

The invention discloses a human cervical cancer radiotherapy resistant cell strain as well as a construction method and application thereof, and belongs to the technical field of tumor radiation biology. In order to solve the technical bottlenecks of clinical disjunction, phenotype instability and single evaluation system of an existing cervical cancer cell radiation resistance model, progressive accumulative irradiation (40 times * 2Gy, the total dose is 80Gy) is performed on human cervical cancer ME180 cells, a clinical radical radiotherapy process is simulated, and a cervical cancer radiation-tolerant strain ME180-R is constructed. In the method, a maintenance irradiation strategy of 2Gy per week is innovatively introduced, so that the radiation resistance phenotype of the cell strain can be stably passed for at least 10 generations. According to the method, a quantitative evaluation system containing multi-dimensional parameters such as D0, Dq and SF2 is established at the same time. The cell strain and the construction method thereof provide reliable and stable preclinical models and tools for transformation medical research such as cervical cancer radiotherapy sensitizer screening, radiation resistance mechanism analysis, individualized radiotherapy scheme optimization and the like.

In the invention, mRNA of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4 and SYTL4 genes, or proteins coded by the genes, show different expression levels between radiation-resistant colorectal cancer cells and radiation-sensitive colorectal cancer cells, and are closely related to the reduction of the survival rate in colorectal cancer patients. Therefore, according to the present invention, an agent for measuring the expression level of mRNA of a gene selected from the group consisting of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4, and SYTL4 or a protein encoded by the gene effectively diagnoses radiation resistance in colorectal cancer or predicts radiation therapy for colorectal cancer. This makes it possible to determine whether to perform radiation therapy and the optimal radiation dose, thereby improving the efficiency and outcome of radiation therapy for colorectal cancer.

The application discloses a kind of based on TRAIL high expression's biomimetic nanoenzyme composite system and preparation method and application.The application is by constructing TRAIL high expression's cell, extracts TRAIL high expression's cell membrane;The cell membrane and Cu 2‑x Se nano particle mixture, solid-liquid separation is washed after, obtains based on TRAIL high expression's Cu 2‑ x Se biomimetic nanoenzyme composite system.This system greatly improves the Cu 2‑x Se catalase and glutathione peroxidase's enzyme ability, can be better under the action of combined X ray Promote the apoptosis of radioresistant cervical cancer cell, so as to better play the role of reversing radioresistance.